Shares of Inogen Inc (NASDAQ:INGN) have been assigned an average rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $103.14.
Several equities research analysts have weighed in on INGN shares. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research report on Thursday, November 9th. BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 target price on shares of Inogen in a research report on Tuesday, September 12th. Leerink Swann restated an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Needham & Company LLC raised their target price on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th.
In related news, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total value of $119,060.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at approximately $119,060. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Raymond Huggenberger sold 14,000 shares of Inogen stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $119.92, for a total value of $1,678,880.00. Following the completion of the sale, the director now owns 7,808 shares in the company, valued at $936,335.36. The disclosure for this sale can be found here. Insiders have sold a total of 99,000 shares of company stock worth $10,926,345 over the last 90 days. Insiders own 5.31% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Schroder Investment Management Group acquired a new stake in Inogen in the 2nd quarter worth about $132,000. Ameritas Investment Partners Inc. boosted its holdings in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares during the last quarter. Sei Investments Co. boosted its holdings in Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after buying an additional 307 shares during the last quarter. Finally, Pinebridge Investments L.P. boosted its holdings in Inogen by 1.6% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after buying an additional 33 shares during the last quarter.
Shares of Inogen (NASDAQ INGN) traded up $0.45 on Tuesday, reaching $119.85. The company’s stock had a trading volume of 123,005 shares, compared to its average volume of 132,575. The firm has a market cap of $2,480.00, a P/E ratio of 83.81, a P/E/G ratio of 4.02 and a beta of 1.13. Inogen has a 12 month low of $62.69 and a 12 month high of $130.05.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm’s revenue for the quarter was up 26.8% compared to the same quarter last year. During the same period last year, the firm earned $0.25 EPS. equities research analysts anticipate that Inogen will post 1.19 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Inogen Inc (INGN) Receives $103.14 Average Target Price from Brokerages” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/06/inogen-inc-ingn-receives-103-14-average-target-price-from-brokerages.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.